Suven Life Sciences secures neuro drug patent from Australia
New Delhi: Suven Life Sciences has been granted a patent from Australia for a drug used in the treatment of disorders associated with neurodegenerative diseases.
The company has been granted one product patent from Australia corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases, it said in a BSE filing.
The patent is valid through 2034.
"We are pleased by the grant of this patent to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally," Suven Life CEO Venkat Jasti said.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd